Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CAM Commission AER Proposal Unfairly Targets Supplements - CRN

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplement manufacturers should not be required to report serious adverse events to FDA, the Council for Responsible Nutrition asserts in Oct. 19 comments on WHCCAMP draft recommendations.

You may also be interested in...



Supplement Labeling Toll-Free AER Number Provision Included In House Bill

Ephedrine alkaloid-containing dietary supplements would be prohibited from sale to people under 18 and limited to "behind-the-counter" distribution under a bill introduced by freshman Rep. Susan Davis (D-Calif.) Oct. 9.

White House Commission To Suggest Mandatory Supplement AE Reporting

The White House Commission on Complementary & Alternative Medicine Policy's report to President Bush will recommend obligatory adverse event reporting by dietary supplement companies.

Supplement AER System Should Follow Food, Not Drug, Model - CRN

An HHS Office of Inspector General report on the Center for Food Safety & Applied Nutrition's Special Nutritionals Adverse Event Monitoring System is inherently flawed, since it incorrectly assumes dietary supplements are comparable to drugs, the Council for Responsible Nutrition says in comments on the report's draft version.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093198

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel